Aphton Appoints David H. Sachs, M.D. to Its Board of Directors.

Business Editors/Health/Medical Writers

BIOWIRE2K

MIAMI--(BUSINESS WIRE)--Sept. 10, 2003

Aphton Corporation (Nasdaq:APHT) today announced the appointment of David H. Sachs, M.D. to Aphton's Board of Directors. This addition expands Aphton's Board of Directors from 5 to 6 members.

Dr. Sachs is a member of the Institute of Medicine of the National Academy of Sciences, Director of the Transplantation Biology Research Center at Massachusetts General Hospital and is the first Paul S. Russell/Warner-Lambert Professor of Surgery (Immunology) at the Harvard Medical School. He graduated from Harvard College, Summa Cum Laude, with an A.B. in Chemistry, received a Diplome d'Etudes Superieures de Sciences in organic chemistry from the University of Paris the following year where he studied as a Fulbright fellow, and received an M.D., Magna Cum Laude, from Harvard Medical School.

Dr. Sachs trained as a surgical intern and research fellow in transplantation at the Massachusetts General Hospital. He then moved to the National Institutes of Health in Bethesda, Maryland, where he later became Chief of the Immunology Branch, National Cancer Institute. During a sabbatical year, Dr. Sachs was Visiting Professor, Department of Cell Research, Wallenberg Laboratory at the University of Uppsala, Sweden, where he initiated studies of the molecular biology of transplantation antigens. He subsequently returned to Massachusetts General Hospital and Harvard Medical School in his current positions.

Dr. Sachs has published over 650 articles in scientific journals. His many research achievements include the discovery of Ia (Class II) antigens and the development of monoclonal antibodies to MHC antigens. He is a member of the Editorial Board of several journals in his field. He has received numerous awards and commendations for scientific achievements, contributions and service in the medical research field. Dr. Sachs serves as Chairman of the Scientific Advisory Board of Immerge BioTherapeutics, Inc. and serves on the Scientific Advisory Board of the Lombard Odier Immunology Fund.

Philip C. Gevas, Aphton's Chairman and Chief Executive Officer, said, "Speaking on behalf of our Board members, we are delighted to welcome Dr. Sachs to our Board, a person with such outstanding credentials and achievements in the fields of immunology and medicine. He brings a wealth of experience, knowledge and ability in these areas, which we believe will prove to be of great benefit to Aphton and our stockholders."

Aphton Corporation ( www.aphton.com ) is a biopharmaceutical company, developing products using its innovative targeted immunotherapy technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and non-cancer diseases. Aphton has strategic alliances with Aventis Pasteur for treating gastrointestinal system and other cancers with G17DT in North America and Europe; and GlaxoSmithKline for reproductive system cancer and non-cancer diseases worldwide.